Introduction: This pooled analysis study aimed to reveal the prognostic relevance of microRNAs (miRNAs) in patients with diffuse large B-cell lymphoma (DLBCL). Materials and Methods: We examined the impact of miRNAs on clinical outcome. Eligible studies were identified and quality assessed using multiple search strategies. Data were extracted from included studies which correlated survival with expression of miRNAs (serum or tissue). Results: We pooled proper studies, and combined the hazard ratios with 95% confidence intervals to estimate strength of the correlations. There were 18 studies including 1950 patients with DLBCL eligible for pooled analysis. We found significant combined HRs for poor overall survival for high expression of miR-21 and low expression of miR-224 in tumor tissue, but for favorable relapse free survival for high expression of miR-21 in serum. Progression free survival was shortened in patients with low expression of miR-199a/b, miR-146b-5p, miR-224 and high expression of miR-222. Conclusion: MiRNAs may act as independent prognostic factors in patients with DLBCL, and useful in risk stratification.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive disease owing to its heterogeneity due to various subtypes, clinical features, genetic abnormalities, responses to treatment and clinical outcomes [1] . DLBCL accounts for 40% of newly-diagnosed nonHodgkin lymphoma. Over a half of patients with DLBCL are considered to be curable after standard chemotherapy [2] . However, there are still patients having poor prognosis even after improved therapy and most of them suffer from refractory to therapy or relapse [3, 4] . Clinicians usually rely on prognostic schemes that imply clinical risk factors to predict the clinical outcome of patients with DLBCL [5] . The International Prognostic Index (IPI) is the most commonly used scheme which includes age, tumor stage, number of extranodal disease sites, serum lactate dehydrogenase concentration and performance status. Nevertheless, there remain some limitations such as poorly characterized and huge heterogeneity resulting in difficulties for predicting the survival.
MicroRNAs regulate target gene expression mostly locating at 3'-untranslated regions through sequence complementarity [6] . MicroRNA genes are frequently located at fragile sites or genomic regions involved in tumor [7] . As the initial miRNA identified in malignant tumor, many researchers have found that miRNAs participate in tumor development in various types of cancers including DLBCL, and potential prognostic role of miRNAs have been widely explored [8] [9] [10] [11] [12] [13] [14] [15] . The relationship between the expression of miRNAs and survival of patients with DLBCL has also been increasingly reported [16] . As the number of patients in individual study is generally small, we aimed to perform a pooled analysis providing a better understand of miRNAs with prognostic relevance. Therefore, a meta-analysis was conducted, included studies that assess miRNAs expression levels associated with clinical outcome in patients with DLBCL to date.
Materials and Methods
The present meta-analysis was performed following the Meta analysis of Observational Studies in Epidemiology group (MOOSE) [17] .
Literature search strategy
The purpose was to identify all primary research articles that assessed the utility of candidate miRNAs as a prognostic factor among patients with DLBCL. A computerized search of MEDLINE was performed via PubMed from January 1990 to December 2015 to identify studies using the following separate search criteria:
1.
(Diffuse large B cell lymphoma OR B cell lymphoma) AND (prognostic OR prognosis OR prognostication OR survive OR survived OR survival) AND (miRNA OR microRNA OR miR) 2. (Lymphoma) AND (prognostic OR prognosis OR prognostication OR survive OR survived OR survival) AND (miRNA OR microRNA OR miR)
Searches were limited to human articles published in the English and Chinese language. Two investigators (Z. Z. and Y. Z.) inspected the titles and abstracts of citations and obtained the full texts. The last date of search was 2nd April 2016.
Inclusion and exclusion criteria
Prognostic miRNA studies were eligible if they met the following initial inclusion criteria: (a) focused on patients with DLBCL; (b) measured the miRNA expression in tumor tissue or blood samples; (c) clearly described miRNA measurement; (d) clearly defined miRNA cut-off value; (e) correlated survival outcomes with miRNA expression (Table 1) and provided sufficient data to estimate the hazard ratio (HR) and 95% CI. Studies were excluded if they were (a) review articles, case reports, laboratory studies, conference abstracts, animal trials or letters; (b) unpublished data; (c) lacked essential data for the pooled calculation.
Data extraction
Eligible articles were reviewed independently by two authors (X. L. and Z. Y.). Disagreements were resolved by consensus and consultation with a third investigator. Data were extracted independently by two authors (Z. Z. and X. L.) using a standard protocol. Information first author, year of publication, country of study in, number of patients, sample type, Ann Arbor stage of DLBCL, International Prognostic Index (IPI) score, method of quantifying miRNA expression, definition of miRNA cut-off value to dichotomize patients into high and low groups, quality of study and hazard ratio (HR) for survival outcome, as well
Quality assessment
The quality of each study was evaluated independently by two authors according to the NewcastleOttawa Quality Assessment Scale (NOS) [19] . For quality assessment, scores ranged from 0 to 9 (best), and studies with scores of 6 or more were rated as high quality. The studies with no less than scores of 5 were included and subsequently pooled analyzed. None of the studies adhered in full to the REMARK (REporting recommendations for tumor MARKer prognostic studies) criteria for studies reporting prognostic tumor markers [20] .
Statistical analysis
Meta-analysis was carried out using the STATA version 12.0 (Stata Corporation, College Station, TX, USA). Cut-off values of miRNAs mentioned in the articles dichotomized patients into high and low groups. HRs and 95% CIs were combined to assess the effective value of miRNA expression on survival. We extracted statistical variables directly if they were described in the study, or calculated from available numerical data in the articles according to the methods described by Tierney et al. [18] . The data from Kaplan-Meier survival curves were reviewed by two independent researchers using Engauge Digitizer version 4.1. We also asked the corresponding authors of eligible articles for additional information and original data needed. HR greater than 1 indicated a worse prognosis in patients and HR less than 1 suggested a better prognosis based on miRNA expression. Inter-study heterogeneity was assessed by visual inspection of forest plots, by performing the Chi-square test (assessing the P value), and by calculating the I 2 statistic [21, 22] . A randomeffects model (the DerSimonian-Laird method) was used when heterogeneity was presented (P<0.05 and/ or I 2 >50%). Otherwise, the fixed-effects model (the Mante-Haenszel method) was used.
Publication bias assessment
Funnel plots with Egger's bias indicator test were used to assess publication bias [23] . Egger's regression intercept was calculated when data from three or more studies were pooled. When publication bias was identified, further analysis was needed for re-estimation which was absent in this study because there was no evidence of publication bias. A P value < 0.05 was considered statistically significant.
Results

Excluded and included studies
A total of 201 articles for consideration were yielded via the search strategies. Title, publication types and abstract assessment identified 28 manuscripts appropriate for [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , for 6 were single studies that were not suitable for pooled analysis, 2 were unable to extract data, and 2 were for other reasons (Fig. 1) . There are 18 papers fulfilling the criteria for meta-analysis [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Inclusion criteria are listed in Table 1 . Disease-free survival (DFS) and event-free survivals (EFS) were considered the same as progression-free survival (PFS) in patients with DLBCL for pooled analysis.
Quality assessment
All 18 eligible studies were assessed for quality according to the NOS. The quality of them varied from 5 to 8, with a mean of 6.2. All studies were included in the subsequent analysis.
Study characteristics
The included studies analyzed a total of 1950 patients with DLBCL from P. R. China, United Kingdom, Sweden, South Korea, Austria, Japan and Denmark, and correlated various miRNA expressions with patients' survival. Eleven studies (61%) were published in 2013 or later. Nine studies (50%) reported on Asians, and 6 (33%) on Caucasians. Details regarding the main characteristics of the included studies are listed in Table 2 . HRs were reported directly in 8 studies and estimated indirectly in the other. The cut-off values varied in these studies. Eight prognostic miRNAs in DLBCL appeared repeatedly in the included studies, and among which 7 miRNAs were screened out for pooled analysis (Table 3) .
Meta-analysis
A summary of the HRs estimated from the entire pooled analysis for all the miRNAs is presented in Table 4 .
miR-21
There were 5 studies assessing miR-21 as a predictor of survival in DLBCL [37, 38, [41] [42] [43] , of which 2 studies used blood samples (n=132) [37, 41] and 3 studies used tumor tissue (n=346) [38, 42, 43] . Once simply pooled, studies with different baselines tended to produce the bias of conclusion. Hence, we performed 3 subgroup analyses according to sample sources, types of survival endpoints and types of Cox hazard regression analysis. As shown in Figure  2 , elevated miR-21 of blood sample was significantly associated with better RFS according to the univariate analysis, with a combined HR 0.533 (95% CI: 0.348 -0.881, P=0.013). No significant inter-study heterogeneity was found (P=0.352, I 2 =0%), so fix-effects model was applied. However, increased miR-21 level was significantly associated with poor OS according to the multivariate analysis [38, 43] , providing a pooled HR 2.672 (95% CI: 1.589 -4.94, P<0.001; Fig. 3) . No significant inter-study heterogeneity was observed (P=0.191, I 2 =41.6%). Lawrie et al. [42] found that high miR-21 expression in tumor tissue was associated with favorable PFS by multivariate analysis (HR=0.77, 95% CI: 0.61-0.97, P=0.025), while, Go et al. [38] proposed higher miR-21 was associated with poor PFS (HR=2.3, 95% CI: 1.1-4.8, P=0.032). The pooled HR of elevated miR-21 level in tissue that predicted PFS was 1.256 
miR-199a/b
Three studies (2 studies presented in one article [40] ) described high miR-199a/b as predictive of favorable PFS in DLBCL (n=119) [40, 49] . MiR-199a/b levels were measured in tissues in all 3 studies, and miR-199a and miR-199b differ very little which might have similar gene target activities, so the results of these 3 studies were proper to be pooled analyzed. Univariate analyses were available in these studies, and when combined, pooled HR 0.403, (95% CI: 0.239 -0.680, P=0.001) was produced. Forest plots are shown in Figure 4 where Fix-effect model is applied (P=0.899, I 2 =0%).
miR-200c
Two studies found miR-200c predictive of OS in DLBCL (n=127) [ 
miR-146b-5p
Two studies [36, 50] assessed low miR146b-5p as predictive of poor PFS in DLBCL (n = 168). The baseline of patients in these 2 studies was approximating similar as they all received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen as the primary treatment. The conclusions were sound by using multivariate analysis. MiR-146b-5p was measured in tissue, and the pooled estimate of risk was 2.610 (95% CI: 1.386 -4.913, P=0.003, Fig. 5 ) with no significant inter-study heterogeneity (P=0.421, I 2 =0%). MiR-146b-5p may act as a poor PFS marker in patients with DLBCL.
miR-224
Two studies [47, 48] showed that elevated expression of miR-224 was predictive of favorable OS and PFS in DLBCL by univariate analysis (n = 426). We calculated a pooled estimate risk for the association between elevated miR-224 expression and OS (HR: 0.344; 95% CI: 0.226-0.524, P<0.001, Fig. 6A ). In addition, a combined HR of PFS was 0.536 (95% CI: 0.397-0.723, P<0.001, Fig. 6B ). Fix-effect model was applied according to their homogeneity (P=0.733 and 0.777, I 2 =0%). The pooled HRs of OS and PFS were consistent, and we may draw a conclusion that miR-224 predicts a better clinical outcome. Table 4 . Summary of HRs of miRNA expression in DLBCL. Abbreviations: OS, overall survival; PFS, progression free survival; RFS, relapse free survival; HR, hazard ratio; CI, confidence interval Fig. 2 . Forest plot showing the combined hazard ratio (HR) from univariate studies for the correlation between high miR-21 serum levels and relapse-free survival (RFS). Each box represents the HR point estimate, and its area is proportional to the weight of the study. The diamond represents the overall summary estimate, with the 95% CI given by its width.
miR-222
Another three studies [34, 44, 46] examined the correlation of high miR-222 tissue expression with PFS (n=522). A combined univariate HR of 2.185 (95% CI: 1.615-2.956, P<0.001) for disease progression was calculated without significant inter-study heterogeneity (P=0.73, I 2 =0%). Forest plots were shown in Figure 7A . Fix-effects model was applied. We did not detect significant publication bias in these 3 studies (Egger's test intercept 2.211, P = 0.781, Fig. 7B ).
Discussion
In order to promote patient survival, it is necessary to extract the most practical data defining tumor subgroups and individual therapy by selected biomarkers. Two molecular subgroups which named germinal center (GCB) and activated B-cell-like (ABC) subtype have already defined by gene expression profiling, and with these, cell of origin of different lymphoid maturation stages is indicated [52] . Nevertheless, difficult predictable clinical course still remains in numerous patients [16] . In this pooled analysis, we sought to identify miRNAs that correlate with survival of patients with DLBCL. Jørgensen et al. [53] have performed a systemic review that identified diagnostic miRNAs biomarkers in patients with DLBCL. As they mentioned very few miRNAs correlated with prognosis, no pooled analysis was performed. Our study focuses on pooled analysis of prognostic miRNAs relevant to 1950 patients with DLBCL. Some independent prognostic factors are indicated via pooled analysis. MiR-21 is often reported to behave as an oncogene in human cancers [54] , and the biological characteristics of which may reveal the correlation between its expression and tumor progression. Common fragile site FRA17B of chromosome 17q23.2 usually amplified in many malignancies where the gene is located in. MiR-21 targets PDCD4, BTG2, Maspin, RECK and TPM1 which causes the enhancement of cell proliferation. Also miR-21 can increase cell growth and enhance migration and invasion, thus promoting aggressive tumor progression by activating of phosphatidylinositol 3-kinase-AKT (PI3K/AKT) signaling [55] [56] [57] [58] [59] . Moreover miR-21 targets Sprouty2 resulting in cellular protrusions enhancement and augment of cell proliferation and migration [60] . Several studies in vitro have shown that miR-21 influences tumor cell growth and apoptosis [61] [62] [63] [64] . Thus, miR-21 acting as a negative prognostic biomarker has been widely accepted. In this study, studies related to miR-21 could not be combined simply due to the different baselines so we divided them into 3 subgroups. However, 3 different results were obtained. In serum, high miR-21 level was able to predict better RFS while in tumor tissues high, miR-21 expression was correlated with poorer OS but could not predict PFS. This was due to following reasons. First, there were discrepancies among selected samples. DLBCL seldom involves bone marrow and therefore tumor markers more likely tend to express in local tissues than in serum. Second, the sample sizes in studies on serum miR-21 are relatively small while those in studies on tissue are larger. Third, results of serum miR-21 are obtained from univariate analyses while those of tissue miR-21 from multivariate analyses. The latter is more reliable than the former. Forth, results reported by Lawrie et al. [41, 42] are different from most of others on the prognostic role of miR-21 [65] [66] [67] [68] [69] , resulting in the heterogeneity among studies. In summary, we conclude that miR-21 is an independent negative factor for DLBCL, consistent with most of published data. The opposite conclusion for RFS might be due to the selection bias of samples, difference of assays, small sample size or bias of analyses.
The other miRNAs of prognostic significance included high expression level of miR199a/b (pooled HR=0.403), miR-224 (pooled HR=0.536 for PFS; pooled HR=0.344 for OS), miR-222 (pooled HR=2.185) and low expression level of miR-146b-5p (pooled HR=2.610). The heterogeneity among studies on miR-200c and miR-34a were too high to obtain significant results of combined HR. Studies of Berglund et al. [35] and Yamagish et al. [51] on miR-200c had similar sample sources, sample sizes, detection assay methods and cutoff values, but completely different results, which was similar to that in solid tumors. This might be due to the ethnic differences between Asian and Caucasian populations as well as small sample sizes, which should be enlarged to obtain more reliable conclusions. It was reported that high miR-34a was associated with favorable survival in solid tumor in pooled analysis [70] , but not observed in our study. The differences among various assay methods might be the major reason. Pooled analysis of only two studies may be inadequate to draw a definite conclusion. Therefore, all the other prognostic miRNAs require further validation in independent and heterogeneous cohorts.
In conclusion, our pooled analysis reveals that miR-21, miR-199a/b, miR-146b-5p, miR-224 and miR-222 appear to have prognostic significance. Further investigation and validation are warranted to this panel of miRNAs in DLBCL based on REMARK guidelines [71] to adhere to the highest standards of scientific validity when reported.
